这其中,有早已稳居该行列的K药、司美格鲁肽,也有新晋的“实力选手”,例如2024年年销售额首度突破百亿美金大关的CD38单抗Darzalex。 对于百亿 ...
(RTTNews) - Genmab A/S (GMAB) Monday announced that Johnson & Johnson (JNJ) has decided not to exercise its option to develop and commercialize HexaBody-CD38 for multiple myeloma, for a worldwide ...
Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...
While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果